Lastly, in my defense, I did say that the steep decline in Savient's stock price last week already took into account all the negativity on Puricase. At the time of publication, Feuerstein's Biotech Select model portfolio was long Genentech, Celgene, Gilead Sciences, AMAG Pharmaceuticals and ...
AstraZeneca, Bayer, Biocartis, Boehringer Ingelheim, Chugai Pharmaceuticals, Daiichi Sankyo, DualityBio, Eisai, Eli Lilly, Frontier Medicines, Hongyun Biotechnology, Merus, Mirati Therapeutics, Monte Rosa, Novartis, Nuvalent, Pfizer, Roche/Genentech, Sanofi, Scorpion Therapeutics, SFJ Pharmaceuticals, Silic...
4. Susanne Klatten - net worth 20.4bn dollars(15bn pounds) The second European on the list, this 55-year-old German has a mixture of cars and pharmaceuticals to thank for her wealth. She inherited 50% of chemical company Altana AG when her parents died, while she and her brother also ...
investors cheered the idea. Nothing quite like it had ever been tried before, and plenty of drugs weren’t living up to their full potential. With a little more focused marketing attention, such a collection of less-than-mainstream pharmaceuticals could...
Lung cancer is the most common cause of cancer-related deaths globally. Although smoking-related lung cancers continue to account for the majority of diagnoses, smoking rates have been decreasing for several decades. Lung cancer in individuals who have n
However, that leaves open the question of how much influence each should exert—and the question has become explicit in the plan for the European Union to review its decades-old legislation governing pharmaceuticals. In the run-up to the legislative process that is scheduled to begin by the ...